Zurcher Kantonalbank Zurich Cantonalbank Buys New Position in CG Oncology, Inc. (NASDAQ:CGON)

Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CG Oncology, Inc. (NASDAQ:CGON) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 6,399 shares of the company’s stock, valued at approximately $241,000.

Other large investors have also recently made changes to their positions in the company. Amalgamated Bank boosted its position in shares of CG Oncology by 107.6% in the 3rd quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock valued at $61,000 after purchasing an additional 840 shares during the period. California State Teachers Retirement System acquired a new stake in CG Oncology during the 1st quarter worth approximately $103,000. Profund Advisors LLC acquired a new stake in CG Oncology during the 2nd quarter worth approximately $300,000. SG Americas Securities LLC acquired a new stake in CG Oncology during the 3rd quarter worth approximately $664,000. Finally, Los Angeles Capital Management LLC acquired a new stake in CG Oncology during the 3rd quarter worth approximately $832,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $34.54, for a total transaction of $34,540.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Wall Street Analysts Forecast Growth

CGON has been the subject of a number of recent research reports. Bank of America reaffirmed a “buy” rating and set a $65.00 price objective on shares of CG Oncology in a research report on Tuesday, October 8th. Roth Mkm initiated coverage on CG Oncology in a research report on Tuesday, August 27th. They set a “buy” rating and a $65.00 price objective for the company. UBS Group initiated coverage on CG Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $60.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and set a $66.00 target price on shares of CG Oncology in a research note on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of CG Oncology in a research note on Friday. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $63.88.

CG Oncology Price Performance

NASDAQ:CGON opened at $34.59 on Monday. The business’s 50-day moving average is $35.78 and its two-hundred day moving average is $34.95. CG Oncology, Inc. has a 12 month low of $25.77 and a 12 month high of $50.23.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.30 million. As a group, equities research analysts predict that CG Oncology, Inc. will post -1.31 EPS for the current year.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.